Factors influencing weight gain after renal transplantation

Weight gain following renal transplantation occurs frequently but has not been investigated quantitatively. A retrospective chart review of 115 adult renal transplant recipients was used to describe patterns of weight gain during the first 5 years after transplantation. Only 23 subjects (21%) were overweight before their transplant. Sixty-six subjects (57%) experienced a weight gain of greater than or equal to 10%, and 49 subjects (43%) were overweight according to Metropolitan relative weight criteria at 1 year after transplantation. There was an inverse correlation between advancing age and weight gain, with the youngest patients (18-29 years) having a 13.3% weight gain and the oldest patients (age greater than 50 years) having the lowest gain of 8.3% at 1 year (P = 0.047). Black recipients experienced a greater weight gain than whites during the first posttransplant year (14.6% vs. 9.0%; P = 0.043), and maintained or increased this difference over the 5-year period. Men and women experienced comparable weight gain during the first year (9.5% vs. 12.1%), but women continued to gain weight throughout the 5-year study (21.0% total weight gain). The men remained stable after the first year (10.8% total weight gain). Recipients who experienced at least a 10% weight gain also increased their serum cholesterol (mean 261 vs. 219) and triglyceride (mean 277 vs. 159) levels significantly, whereas those without weight gain did not. Weight gain did not correlate with cumulative steroid dose, donor source (living-related versus cadaver), rejection history, pre-existing obesity, the number of months on dialysis before transplantation, or posttransplant renal function. Posttransplant weight gain is related mainly to demographic factors, not to treatment factors associated with the transplant. The average weight gain during the first year after renal transplantation is approximately 10%. This increased weight, coupled with changes in lipid metabolism, may be significant in terms of altering risk from cardiovascular morbidity.

Hepatitis C is a poor prognostic indicator in black kidney transplant recipients

BACKGROUND

The significance of hepatitis C in kidney transplant recipients is unclear. The prevalence of antibodies to hepatitis C among candidates for transplantation is up to 50% in some centers.

METHODS

We screened 640 frozen serum samples obtained pretransplantation from all kidney recipients at the Medical College of Wisconsin between January 1979 and March 1990 for antibody to hepatitis C using the second generation immunoassay. Charts were reviewed from all hepatitis C antibody-positive (anti-HCV+) patients and 256 randomly chosen hepatitis C antibody negative (anti-HCV-) controls. Actuarial patient and graft survival in these two groups were determined.

RESULTS

The prevalence of anti-HCV was 8.3%. Blacks and i.v. drug users were disproportionately represented in the anti-HCV+ group. Of the anti-HCV+ patients, 18.9% developed chronic hepatitis independent of race. Black anti-HCV+ patients had a 5-year graft survival of 28 +/- 11% compared to 67 +/- 7% in black anti-HCV- patients (P = 0.003). Black anti-HCV-, white anti-HCV-, and white anti-HCV+ patients all had similar graft survival. Anti-HCV was not a poor prognostic indicator for overall patient survival or the development of aplastic anemia and malignancies including hepatocellular carcinoma.

CONCLUSIONS

Anti-HCV is a significant risk factor for reduced kidney graft survival in blacks apart from i.v. drug abuse. Black anti-HCV- patients had graft survival similar to white transplant recipients, indicating that anti-HCV may be one marker for the poorer graft survival in blacks that has been observed in most transplant programs. Anti-HCV in kidney transplant recipients increases the risk for the development of chronic hepatitis post-transplant.

Evaluation of renal transplant dysfunction using color Doppler sonography

Color Doppler sonography (CDS) detects changes in renal blood flow that may be useful in evaluating renal transplant dysfunction (RTD). To assess the performance of CDS as a clinical test, we reviewed results from 223 CDS measurements in 130 renal transplant recipients during a 26 month period. Spectral wave forms were characterized by pulsatility index (PI) (maximum frequency shift minus minimum frequency shift divided by mean frequency shift). In 27 individuals with stable renal function, mean PI was 1.80 +/- 0.23 (S.D.). Abnormal PI were subsequently defined as greater than two S.D. more than the mean (PI greater than or equal to 2.3). CDS performed during the early post-transplant period (n = 91) could not differentiate acute tubular necrosis (ATN), obstruction and rejection. Abnormal studies were seen in 35 of 46 instances of ATN and in three of obstruction. In 132 studies done after the postoperative period, CDS became abnormal during rejection episodes in only 45 of 71 instances (sensitivity rate of 63 per cent). When abnormal, CDS was highly suggestive of rejection, however (45 of 49, 92 per cent specificity). Cyclosporine toxicity was not associated with abnormal pulsatility (zero of seven). In 68 instances, CDS and conventional 99mTc DTPA renogram flow studies were performed together within 24 hours. CDS was more sensitive in detecting rejection but the difference did not reach statistical significance (25 of 36 versus 17 of 36). The major advantage of CDS over conventional radionuclide imaging relates to its shorter examination time, lower cost and portable capabilities. CDS will probably become the roentgenologic imaging modality of choice in renal transplantation.

Functional capacity and activity level before and after renal transplantation

Functional capacity and activity level were measured among 9 renal transplant recipients prior to transplantation (T1), 6 weeks (T2), and 16 weeks (T3) after transplantation. Functional capacity was measured by a symptom-limited treadmill test. The Human Activity Profile was used to obtain self-reported activity level. A 24% improvement in functional capacity was found from T1 to T2 with only a 5% improvement from T2 to T3 (p less than .001). In contrast, significant improvement in activity level was not present until after T2. Although activity level increased from T1 to T3 (p less than .01), it continued to be low in comparison with age/gender matched normative data.